Advertisement

Clinical Syndromes: Cryptococcosis

  • Romain Guery
  • Fanny Lanternier
  • Olivier Lortholary
Chapter

Abstract

Human cryptococcosis is caused by two species complexes, C. neoformans and C. gattii. As HIV/AIDS is the main risk factor of cryptococcosis, this opportunistic infection also occurs in solid organ transplant recipients and subjects with primary or acquired impaired cell-mediated immunity. However, there is increasing number of cases in otherwise healthy individuals particularly in relation to C. gattii infection. Lung and central nervous system are commonly affected. Meningoencephalitis is always fatal without treatment, and mortality approaches 20% in developed countries. Diagnosis is easy regarding performances of new point-of-care diagnostic assay such as lateral flow assay in serum and cerebrospinal fluid (CSF). A complete work-up for dissemination should be done in case of positive sample for Cryptococcus spp. Most severe patients should be treated with combination of liposomal amphotericin B (or amphotericin B deoxycholate if the former is not available) and flucytosine for at least 2 weeks followed by consolidation therapy with fluconazole for 8–10 weeks and finally with maintenance therapy with low doses of fluconazole. Elevated intracranial pressure should be promptly evaluated as its control has a significant benefit on mortality.

Suggested Readings

  1. Beardsley J, Wolbers M, Kibengo FM et al (2016) Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. N Engl J Med 374:542–554CrossRefGoogle Scholar
  2. Boulware DR, Meya DB, Muzoora C et al (2014) Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 370:2487–2498CrossRefGoogle Scholar
  3. Chen SC-A, Meyer W, Sorrell TC (2014) Cryptococcus gattii infections. Clin Microbiol Rev 27:980–1024CrossRefGoogle Scholar
  4. Day JN, Chau TTH, Wolbers M et al (2013) Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 368:1291–1302CrossRefGoogle Scholar
  5. Guery R, Lanternier F, Pilmis B, Lortholary O Cryptococcus neoformans (cryptococcosis) - infectious disease and antimicrobial agents. In: antimicrobe.org. http://www.antimicrobe.org/new/f04.asp. Accessed 27 Apr 2017
  6. Kwon-Chung KJ, Bennett JE, Wickes BL et al (2017) The case for adopting the “species complex” nomenclature for the etiologic agents of cryptococcosis. mSphere 2:e00357–e00316CrossRefGoogle Scholar
  7. May RC, Stone NRH, Wiesner DL, Bicanic T, Nielsen K (2016) Cryptococcus: from environmental saprophyte to global pathogen. Nat Rev Microbiol 14:106–117CrossRefGoogle Scholar
  8. Perfect JR, Dismukes WE, Dromer F et al (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50:291–322CrossRefGoogle Scholar
  9. Sun H-Y, Alexander BD, Huprikar S et al (2015) Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression. Clin Infect Dis 60:36–44CrossRefGoogle Scholar
  10. Williamson PR, Jarvis JN, Panackal AA, Fisher MC, Molloy SF, Loyse A, Harrison TS (2016) Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. Nat Rev Neurol. doi:  https://doi.org/10.1038/nrneurol.2016.167CrossRefGoogle Scholar

References

  1. 1.
    Molloy SF, Kanyama C, Heyderman RS, Loyse A, Kouanfack C, Chanda D et al (2018) Antifungal combinations for treatment of cryptococcal meningitis in Africa. N Engl J Med 378(11):1004–1017CrossRefGoogle Scholar
  2. 2.
    Hamill RJ, Sobel JD, El-Sadr W, Johnson PC, Graybill JR, Javaly K et al (2010) Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis Off Publ Infect Dis Soc Am 51(2):225–232CrossRefGoogle Scholar
  3. 3.
    Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J et al (1997) Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS Lond Engl 11(12):1463–1471CrossRefGoogle Scholar
  4. 4.
    Sun H-Y, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM et al (2009) Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis Off Publ Infect Dis Soc Am 49(11):1721–1728CrossRefGoogle Scholar
  5. 5.
    Powderly WG, Cloud GA, Dismukes WE, Saag MS (1994) Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis Off Publ Infect Dis Soc Am 18(5):789–792CrossRefGoogle Scholar
  6. 6.
    Aberg JA, Watson J, Segal M, Chang LW (2000) Clinical utility of monitoring serum cryptococcal antigen (sCRAG) titers in patients with AIDS-related cryptococcal disease. HIV Clin Trials 1(1):1–6CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Romain Guery
    • 1
  • Fanny Lanternier
    • 1
  • Olivier Lortholary
    • 1
  1. 1.Université Paris Descartes, Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants Malades, Centre d’Infectiologie Necker-Pasteur and Institut ImagineParisFrance

Personalised recommendations